125 results
Page 4 of 7
8-K
EX-99.1
mcy8kp7 hp2
28 Mar 19
Recro Pharma Appoints Arnaud Ajdler to Its Board of Directors
6:05am
8-K
EX-99.1
1sy1ntu
22 Mar 19
Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam
4:17pm
8-K/A
ld5 6nqzp
6 Mar 19
Entry into a Material Definitive Agreement
5:02pm
8-K/A
EX-10.1
q8cycmq yuohy6
6 Mar 19
Entry into a Material Definitive Agreement
5:02pm
8-K
EX-10.1
dc7op0kr1bnelr
4 Mar 19
Entry into a Material Definitive Agreement
7:05am
424B5
etzneu6sm zoi4vv54db
19 Feb 19
Prospectus supplement for primary offering
8:39am
8-K
EX-99.2
8twnyi4w3 ad
19 Feb 19
Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018
7:05am
8-K
EX-99.1
6jae35my9t
19 Feb 19
Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018
7:05am
8-K
EX-99.1
otczizx53 w4ardp
7 Jan 19
Other Events
7:01am
8-K
EX-10.1
bvbzkn wg1ctknc54r
4 Jan 19
Entry into a Material Definitive Agreement
4:23pm
8-K
EX-99.1
12su cdmb3upkdp
10 Dec 18
Other Events
2:07pm
8-K
EX-99.1
iu1a7u1av8x7gffw3x
7 Nov 18
Recro Pharma Reports Third Quarter 2018 Financial Results
7:06am
8-K
EX-99.2
ahz5y mvew4w
7 Nov 18
Recro Pharma Reports Third Quarter 2018 Financial Results
7:06am
8-K
EX-99.1
c6m6m3f f32r5u2f
9 Oct 18
Recro Pharma Announces PDUFA Date for IV Meloxicam
6:07am
8-K
EX-99.2
rfqe9jo 353d
1 Oct 18
Recro Announces Expansion of CDMO Service Capabilities
12:00am